Expired activity
Please go to the PowerPak
homepage and select a course.
Getting to Know the New JAKs on the Block: Pharmacy-Focused Insights for Atopic Dermatitis and Alopecia Areata
Provided by Boston University School of Medicine and The University of Rhode Island College of Pharmacy.
This activity is supported by an independent educational grant from Pfizer.
Published
October 30, 2021
Expires
October 30, 2022
Estimated Time to Complete
1 hour and 45 minutes
Number of Credits
1.75
Program Description
This activity provides targeted education to community pharmacists and managed health care professionals for the emerging therapies on the horizon in moderate-to-severe atopic dermatitis (AD) and alopecia areata (AA). Also included are brief vignettes of actual patient interviews. Their perspectives will provide insight into the daily challenges and quality of life issues that can occur while living with AD and AA.
Our experts discuss the connection between AD and AA and compare/contrast their differences; the challenges surrounding the available treatments for AD and AA, with a large unmet need for alternative and more effective therapies with a good safety profile for long-term use; how the Janus kinase (JAK)-signal transducer activator of transcription pathways have an important role in the pathogenesis of AD and AA; the latest clinical trial efficacy, safety, and tolerability data of available and emerging oral JAK inhibitors currently under investigation for AD and AA; and the potential place in therapy and monitoring aspects for the emerging agents in AD and AA.
Furthermore, the experts discuss how the health disparities of patients with AA and/or AD leads to lower medication access and they explore the unique role of the pharmacist in providing education and obtaining prior authorization to medications for patients with AA and/or AD.
Intended Audience
This curriculum is intended for a broad audience of community pharmacists, dermatologic specialty pharmacists, and managed health care professions involved in the care and treatment of patients with AD and/or AA.
Educational Objectives
After completing this activity, participants should be able to:
- Explore the changing paradigm of Alopecia Areata (AA) and Atopic Dermatitis (AD) disease presentation and treatment approach.
- Assess and interpret the latest clinical trial data among emerging oral agents in AA and/or AD and terms of therapeutic target, safety, efficacy, and tolerability.
- Recognize the potential place in therapy and monitoring aspects for the emerging agents in AA and AD in order to effectively engage patients in shared decision-making for their treatment plan.
- Outline a plan to proactively identify and remove barriers for health maintenance services and medication access in underserved patients with AA and/or AD.
Accreditor Disclosure of Conflicts of Interest Policy
Boston University School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
Faculty Info
Amanuel Kehasse, PharmD, PhD
Course Director
Clinical Pharmacy Specialist in Autoimmune and
Interstitial lung disease
Boston Medical Center Health System
Boston, MA
Dr. Kehasse earned his Bachelor of Pharmacy degree (BPharm) from University of Asmara, College of Health Sciences in 2003 in Eritrea. Dr. Kehasse then joined the Orotta School of Medicine and served as an assistant lecturer of Biochemistry until 2005. At the same time, he served as the general secretary of Eritrean Pharmaceutical Association (EriPA).
In 2005, he immigrated to the United States of America and earned his Doctor of Philosophy (PhD) in medical biochemistry from Boston University School of Medicine, Division of Graduate Medical Sciences in 2012. He then pursued his post-doctoral research fellowship at The Buck Institute -University of California San Francisco (UCSF). His research focused on post translational modification of proteins and biomarker discovery, and has published his research findings at American Journal of Pathology, Journal of Experimental Medicine and Oncotarget.
In 2015, Dr. Kehasse became a registered pharmacist (RPh) in the State of Massachusetts. He then pursued his Pharmacy studies at Massachusetts College of Pharmacy and Health Sciences (MCPHS) and earned his Doctor of Pharmacy (PharmD) degree in 2017.
Currently, Dr. Kehasse is a clinical pharmacy specialist of autoimmune diseases and pulmonary diseases at Boston Medical Center, with special interest in clinical and outcomes research.
Dana McCormick, RPh, FAMCP
Director of Pharmacy
Blue Cross Blue Shield of Texas
Richardson, TX
Dana currently is serving as the Director Pharmacy overseeing clinical account consulting services for Blue Cross Blue Shield of Texas. She has worked in many areas of pharmacy practice including PBMs, health plans, health plan associations, and the pharmaceutical industry. Dana has been active member of AMCP and served as the President of the Board of Directors. She got her degree in Biology at Southwestern University before completing her pharmacy degree at The University of Texas College of Pharmacy in Austin, Texas.
Lynne J. Goldberg, MD
Jag Bhawan Professor of Dermatology and
Pathology and Laboratory Medicine
Boston University School of Medicine
Director, Hair Clinic
Boston Medical Center
Boston, MA
Dr. Goldberg completed residencies in both internal medicine at New York University and dermatology at Albert Einstein College of Medicine before her fellowship in dermatopathology at Boston University. She is currently the Jag Bhawan Professor of Dermatology and Pathology & Laboratory Medicine at Boston University School of Medicine, where she divides her time between the practices of clinical dermatology and dermatopathology.
Dr. Goldberg has developed expertise in the clinical and histopathological evaluation of alopecia, and runs the Hair Clinic at Boston Medical Center. She has served on the Board of the American Hair Research Society and the Editorial Board of the Journal of Cutaneous Pathology, and is a Scientific Advisor to the Cicatricial Alopecia Research Foundation. She has a passion for teaching, has won several teaching awards, and lectures internationally on alopecia.
Peter A Lio, MD
Assistant Professor of Clinical Dermatology and Pediatrics
Northwestern Feinberg School of Medicine
Director, Chicago Integrative Eczema Center
Founding Partner, Medical Dermatology
Associates of Chicago
Chicago, IL
Peter Lio is a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine. Dr. Lio received his medical degree from Harvard Medical School, completed his internship in Pediatrics at Boston Children’s Hospital, and his Dermatology training at Harvard where he served as Chief Resident in Dermatology. While at Harvard, he received formal training in acupuncture. Dr. Lio is the founding director of the Chicago Integrative Eczema Center, and currently serves as a board member and scientific advisory committee member for the National Eczema Association. He has over 100 publications and 2 textbooks.
Faculty Disclosures
Peter Lio, MD is on the advisory board for Johnson and Johnson, DermTap, Inc., Intraderm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Syncere Skin Systems, DermVeda, gpower, inc. UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Arbonne, YobeeCare, Inc., Bodwell, ASLAN Pharmaceuticals, Almirall, MaskSense, Castle Biosciences, and Verrica Pharmaceuticals Inc. He is a stockholder for Modernizing Medicine, LearnHealth/LearnSkin, and Medable. He is a speaker for Pierre Fabre Dermatologie, Regeneron, La Roche-Posay Laboratorie Pharmaceutique, Galderma USA, Eli Lilly and Company, and Pfizer Inc. Dr. Lio is a consultant for Exeltis, Theraplex, Odeza LLC, L'Oreal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Ltd, Eli Lilly and Company, Unilever, and Dermira, Amyris, Inc., LEO Laboratories, Ltd, Burt’s Bees, Kimberly Clark, Sonica, LLC, and Concerto Biosciences. Dr. Lio receives research support from AOBiome, LLC, Regeneron, and AbbVie. Dr. Lio receives royalties from Theraplex.
Dr. Kehasse, Ms. McCormick, and Dr. Goldberg have no relevant financial relationships to disclose.
Accreditor Disclosures
The following members of Boston University School of Medicine’s Continuing Medical Education Office, have no relevant financial relationships to disclose:
Natalie Sanfratello, MPH, Program Manager
Michael Burk, Senior Program Manager
Dana Frazier-Price MS, CHCP, Grant Development Manager
Jessica Martin, PhD, Consultant medical editor
Mary-Jane Kanaczet, M. Ed., Director, Office of Continuing Professional Development,
College of Pharmacy, University of Rhode Island, has no relevant financial relationships to disclose.
Accreditation Statement
ACPE
The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This is an application-based educational activity. Pharmacists will receive 1.75 contact hour (0.175 CEUS) for the educational activity. No partial credit is available. Initial Release Date: October 30, 2021. Planned Expiration Date: October 30, 2022.
UAN: 0060-9999-21-053-H01-P
Disclosure of Unlabeled Use
Faculty members do plan to discuss unlabeled/investigational uses of a commercial product.
Disclaimer
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
How to Earn Credit
Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
For information about the accreditation of this program, please contact cme@bu.edu.
To view Boston University’s Privacy Policy, please see https://cme.bu.edu/content/privacy-statement
© Trustees of Boston University, 2021
